

# Novavax COVID-19 Vaccine Flyer

## (FDA Emergency Use Authorization)

The Centers for Disease Control and Prevention (CDC) approved the Advisory Committee on Immunization Practices (ACIP) recommendation for the **NOVAVAX COVID-19** vaccine, named NVX-CoV2373.

### Key Considerations to Note

- Emergency Use Authorization (EUA) has been granted for those 12 years of age and up as a primary two-dose series and as an updated vaccine for those who have previously been vaccinated.
- Novavax COVID-19 is a protein subunit vaccine; it contains harmless proteins of the COVID virus with an adjuvant that helps the body's immune system respond to the virus in the future.
- This mechanism of action has been used for more than 30 years in other vaccines including those for hepatitis B, the flu and whooping cough.
- The vaccine does NOT contain eggs, preservatives, latex or metals.
- The recommended dosing includes:
  - Two doses in the primary series, administered as an intramuscular injection in the upper arm.
  - The second dose is given 8 weeks after the first dose.
  - Immunocompromised individuals may receive extra doses, based upon health care provider recommendation.
  - People aged 12 years and older who got COVID-19 vaccines before September 12, 2023 should get one updated Pfizer-BioNTech, Moderna or Novavax COVID-19 vaccine.

**Check the reference link provided for the most current information.**

[Novavax COVID-19 Vaccine, Adjuvanted | FDA](#)

